Inari Medical, Inc. announced the first patient enrollment in the PEERLESS II study. This prospective, global, multi-center randomized controlled trial (RCT) compares the outcomes of intermediate-risk acute pulmonary embolism (PE) patients treated with the FlowTriever®? System against those treated with traditional anticoagulation therapy alone.

The first patient was enrolled by Dr. William H. Matthai, Jr., Director of Clinical Cardiology Research and Professor of Clinical Medicine (Cardiovascular Medicine) at Penn Presbyterian Medical Center at the University of Pennsylvania. PEERLESS II is the largest study of its kind and will include up to 1,200 randomized patients at up to 100 global centers. The study is running alongside the currently enrolling PEERLESS RCT, which is comparing PETriever to catheter-directed thrombolysis.

Both trials aim to generate the high-quality clinical evidence needed to move the field forward and establish FlowTriever as the optimal therapy for intermediate-risk PE patients.